American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

Funding Acknowledgements

The American College of Rheumatology, the European League Against Rheumatism, and the NIH (grant AR-47785). Dr. Smolen has received consulting fees, speaking fees, and/or honoraria from Amgen, Abbott, Centocor, Schering-Plough, Wyeth, Bristol-Myers Squibb, Roche, UCB, and AstaZeneca (less than

0 000 each); he has received grants from Schering-Plough, Roche, UCB, Bristol-Myers Squibb, and Abbott. Dr. Aletaha has received consulting fees, speaking fees, and/or honoraria from Abbott, Roche, UCB, Bristol-Myers Squibb, Schering-Plough, and Wyeth (less than 0 000 each). Dr. Allaart has received consulting fees, speaking fees, and/or honoraria from Schering-Plough, Centocor, and UCB (less than 0 000 each). Dr. Bathon has received consulting fees, speaking fees, and/or honoraria from Crescendo Biosciences and Roche (less than 0 000 each); she has received research contracts from Biogen Idec. Dr. Brown has received speaking fees and/or honoraria from Schering-Plough, Abbott, and Pfizer (less than 0 000 each). Dr. Matucci-Cerinic has provided paid consul- tation to Pfizer, Actelion, and Schering (less than 0 000 each). Dr. Choi has received honoraria for serving on advisory boards for TAP Pharmaceuticals and Savient (less than 0 000 each). Dr. Furst has received consulting fees, speaking fees, and/or honoraria from Abbott, Actelion, Amgen, Bristol-Myers Squibb, Biogen Idec, Centocor, Genentech, Gilead, GlaxoSmithKline, Merck, Nitec, Novartis, UCB, Wyeth, and Xoma (less than 0 000 each); he has received research funding from Abbott, Actelion, Amgen, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Nitec, Novartis, Roche, UCB, Wyeth, and Xoma. Dr. Gomez-Reino has received consulting fees, speaking fees, and/or hono- raria from Schering-Plough, Bristol-Myers Squibb, Wyeth, Roche, and UCB (less than 0 000 each). Dr. Khanna has received consulting fees, speaking fees, and/or honoraria from Abbott and UCB (less than 0 000 each). Dr. Landewe has received consulting fees, speaking fees, and/or honoraria from Abbott, Centocor, Schering-Plough, Wyeth, Pfizer, UCB, Merck, Bristol-Myers Squibb, and Amgen (less than 0 000 each). Dr. Martin-Mola has received consulting fees from Merck, Sharp, and Dohme, Pfizer, and Roche (less than 0 000 each). Dr. Pincus has received consulting fees, speaking fees, and/or honoraria from Amgen, Abbott, Bristol-Myers Squibb, Centocor, UCB, Wyeth, and Genentech (less than 0 000 each) and research grants from Amgen, Bristol-Myers Squibb, UCB, and Centocor. Dr. Simon has received consulting fees from Affinergy, AstraZeneca, Abraxis, Alpha Rx, Nuvo/Dimethaid Research, Roche, Pfizer, Novartis, PLx Pharma, Hisamitsu, Dr Reddys, Avanir, Cerimon, Alimera, Paraexel, Nitec, Bayer, Rigel, Chelsea, Regeneron, Cypress Biosciences, Nicox, Biocryst, Extera, Wyeth, Solace, Puretech-ventures, White Mountain Pharma, Abbott, Omeros, Jazz, Takeda, Teva, Zydus, Proprius, Alder, Cephalon, Seprecor, Purdue, EMD Merck Se- rono, Altea, Talagen, TiGenix, Antigenics, Forest, Genzyme, CaloSyn, King, Pozen, IL Pharma, Analgesic Solutions, and US WorldMeds (less than 0 000 each) and from Savient and Horizon (more than 0 000 each); owns stock or stock options in Savient; and has provided paid consultation to Leerink Swann, Luxor, Nomura, and Fidelity, investment analysis firms. Dr. Sokka has received consulting fees, speaking fees, and/or honoraria from Abbott, Pfizer, and UCB (less than 0 000 each). Dr.Tugwell has received consulting fees from Bristol-Myers Squibb, Chelsea, and UCB (more than 0 000 each); he hasreceived research grants from Aventis (HMR), Biomatrix, Cigna, Genzyme, Merck, Novar- tis, Parke Davis, Pfizer, Rhone-Poulenc, Sandoz, and SmithKline Beecham. Dr. Zink has received speaking fees from Abbott, Bristol- Myers Squibb, Roche, Wyeth, and UCB (less than 0,000 each).